Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo has secured approvals from the US Food and Drug Administration for abbreviated new drug applications referencing GlaxoSmithKline's Nicorette White Ice Mint Gum (nicotine polacrilex gum 2 mg and 4 mg).
Subscribe to our email newsletter
These products will be packaged and marketed as store brands or retailer 'own label' brands and provide consumers with high-quality, value alternatives to Nicorette White Ice Mint Gum.
Nicorette White Ice Mint Gum is used to help patients quit smoking by reducing nicotine withdrawal symptoms. Annual sales for the 12 months ending November 2016 were $79m.
Perrigo consumer healthcare Americas executive vice president & president Jeff Needham said: "This product approval reflects Perrigo's commitment to providing customers and consumers with high quality value alternatives to important OTC products.
“Perrigo's innovative OTC product offerings are what drive value for our customers as they keep pace with changing consumer preferences."